PFIZER INC

Pfizer’s 73%‑effective Lyme vaccine hits Phase 3 milestones, sparking regulatory plans but tempered market response as investors weigh commercial prospects and competitive challenges.

Pfizer’s 2026 investor activity shows heavy institutional buying while Medicare price talks loom, hinting at future revenue impacts.

Pfizer’s 2026 earnings miss sparks a sharp shift to “hold” and rising bearish sentiment, as price‑control pressures and safety concerns threaten the pharma giant’s growth legacy.